Viral Vaccine Cell Culture Media Market is expected to
London, June 23, 2022 (GLOBE NEWSWIRE) — Root analysis announced the addition of “Culture of Viral Vaccine Cells Media Market, 2022-2035” against its list of offers.
Vaccine production is a highly regulated and difficult process; specifically, the production of viral components or whole viruses adds further complexity. In addition, it is essential that the vaccine cultures are free from contamination and are highly effective. In order to mitigate the aforementioned challenges, pharmaceutical and biotechnology companies are gradually adopting viral vaccine cell culture media for vaccine manufacturing.
To order this 175+ page report, which includes over 80 figures and over 100 tables, please visit https://www.rootsanalysis.com/reports/viral-vaccine-cell-culture-media-market.html
Key market information
Currently, more than 80 cell culture media for viral vaccines are offered by several players
This segment of the industry is dominated by the presence of large players (more than 200 employees) and start-ups/small players (2-50 employees), who collectively represent more than 75% of the total viral vaccine cell culture media developers. Moreover, about 35% of companies were founded after 2010.
70% of cell culture media are intended to support cell culture in suspension
Serum-free media have become the most preferred option for cell suspension culture, accounting for over 65% of all viral vaccine cell culture media. Next come animal-free media (38%) and protein-free media (17%), which are preferred for cell suspension cultures.
Multiple initiatives dedicated to viral vaccine cell culture media have been reported, since 2015
More than 55% of the overall expansions were focused on new facility expansions. Additionally, partnering activity in this space has grown at a CAGR of over 38%, between 2015 and 2021. Acquisitions have emerged as the most popular type of partnering model adopted by industry stakeholders (59%).
Over 125 vaccine developers and contract manufacturers are potential strategic partners for viral vaccine cell culture media developers
About 40% of vaccine developers and contract manufacturers are based in North America, followed by those located in Asia-Pacific and the rest of the world (31%). Additionally, 38% of vaccine developers and contractors are established players (companies created before 2000).
Over 2,800 patents have been filed/granted for viral vaccine cell culture media, through 2021
Based on the distribution of intellectual property worldwide, R&D activity related to viral vaccine cell culture media is largely concentrated in the United States (50%). Moreover, the majority of patents in this field have been filed by manufacturers (58%).
Global demand for viral vaccines is expected to grow at a CAGR of 1.5%, over the period 2022-2035
Clinical demand for the viral vaccine is expected to increase at a CAGR of 2.6%. Additionally, the demand for viral vaccines in Asia-Pacific is expected to increase at a CAGR of 1.4%.
Europe and Asia-Pacific are expected to capture over 65% market share in 2035
In terms of cell culture type, the current market is driven by suspension cell cultures (65%); this trend is unlikely to change in the foreseeable future. Additionally, based on the scale of operation, business operations are expected to capture the majority of the revenue share (90%) of the overall market in 2035.
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/viral-vaccine-cell-culture-media-market/request-sample.html
Answers to key questions
- Who are the main players involved in the development of cell culture media for viral vaccines?
- What type of cell culture is most commonly offered by developers of cell culture media for viral vaccines?
- What types of partnership models are commonly adopted by players engaged in this industry?
- What is the relative competitiveness of different viral vaccine cell culture media?
- Who are the most likely partners for developers of vaccine cell culture media?
- What are the main challenges currently facing players in this industry?
- What are the anticipated future trends related to cell culture media developers for viral vaccines?
- How is the current and future market opportunity likely to be distributed across key market segments?
The financial opportunity in the cell culture media for viral vaccines market has been analyzed in the following segments:
Type of cell culture
- Adherent cell culture
- Suspension cell culture
Type of cell culture medium
- Media without animal component
- Protein-free media
- Serum-free media
Scale of operation
End user type
- Industry players
- Non-industrial players
Key geographic regions
- North America
- Asia Pacific
- Rest of the world
The report includes profiles of key players (listed below); each profile presents an overview of the company, details related to its financial information, product portfolios and insights into the future.
- Creative biolabs
- Jianshun Biosciences
- Thermo Fisher Scientific
- ATZ Laboratories
- OPM Biosciences
For more details, please visit
https://www.rootsanalysis.com/reports/viral-vaccine-cell-culture-media-market.html or email us at [email protected]
You might also be interested in the following titles:
- Subcutaneous Biologics, Technologies and Drug Delivery Systems Market (4th Edition): Industry Trends and Global Forecast, 2022 – 2035
- Peptide Therapeutics: Contract API Manufacturing Market: Industry Trends and Global Forecast, 2022-2035
- Vaccine Contract Manufacturing (CMO) Market (3rd Edition): Industry Trends and Global Forecast, 2021-2030